Abstract
Background: Poor quality use of medicines (QUM) has adverse outcomes. Governments implement essential medicines (EM) policies with limited information on which policies are most effective. Methods: We analysed data on policy implementation from WHO surveys in 2007 and 2011, and QUM data from surveys between 2006 and 2012 in developing and transitional countries. We compared QUM scores in countries that did or did not implement specific policies and regressed QUM composite scores on the numbers of policies implemented. We compared the ranking of policies in this and 2 previous studies, one from the same WHO databases (2003-2007) the other from data obtained during country visits in South-East Asia (2010-2015). The rankings of a common set of 17 policies were correlated and we identified those that were consistently highly ranked. Findings: Fifty-three countries had data on both QUM and policy implementation. Forty policies were associated with effect sizes ranging from +13% to -5%. There was a positive correlation between the composite QUM indicator and the number of policies reported implemented: (r) = 0.437 (95% CI 0.188 to 0.632). Comparison of policy rankings between the present and previous studies showed a positive correlation with the WHO 2003-7 study: Spearman's rank correlation coefficient 0.498 (95% CI 0.022 to 0.789). Across the 3 studies 5 policies were in the top 5 ranked positions 11 out of a possible 15 times. They were: drugs available free at the point of care; presence of a government QUM unit; undergraduate training of prescribers in standard treatment guidelines, antibiotics not available without prescription and generic substitution in the public sector. Interpretation: Certain EM policies are associated with better QUM and impact increases with co-implementation. Analysis across three datasets provides a policy short-list as a minimum investment by countries trying to improve QUM and reduce antimicrobial drug misuse. Funding: No direct funding was provided for this work. Declaration of Interest: All authors have either worked for (KH, VI, GF, DH) or had a working relationship (SM, MJ, AM) with WHO at some stage in their professional lives. All authors declare that they have no other competing interests. Ethical Approval: All work involved secondary analyses of data collected for other purposes. Data were aggregated at the level of countries or policies, not individuals, so research ethics board approval was not required.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.